Search results

For any in vitro protocol or research study where a source of human FXIII deficient plasma is required.

Measurement of factor XII (FXII or factor hageman) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent).For any in vitro protocol or research study where a source of human FXII deficient plasma is required.

Measurement of factor X (FX or stuart factor) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FX deficient plasma is required

Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.

Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.

Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.

For any in vitro protocol or research study where a source of human fibrinogen deficient plasma is required.

Thrombin (IIa), anti-human, mouse, IgG (monoclonal)

Thrombin, human, purified, inactivated

Thrombin (α form), human, purified